India's Health Economic-Industrial Complex from a Latin American Perspective
DOI:
https://doi.org/10.24215/26183188e132Keywords:
Health Economic-Industrial Complex, India, S&T and health, Latin AmericaAbstract
This article describes and characterizes the Indian Health Economic-Industrial Complex. It adopts a “reasoned history” approach based on a review of Indian and Latin American authors and official documents. The analysis of the Indian experience allows outlining aspects of similarity and lessons for the conceptualization and formulation of health policies in Latin America, as it involves common challenges, both in terms of reducing the importation of medicines and medical equipment, as well as the need to strengthen access to medicines and medical treatments.
References
Abrol, D., Prajapati, P. y Singh, N. (2011). Globalization of the Indian Pharmaceutical Industry: Implications for Innovation. International Journal of Institutions and Economies, 3(2), 327-365.
Abrol, D., Sundararaman, T., Madhavan, H. y Joseph, K. J. (2016). Building inclusive health innovation systems: lessons from India. Cadernos de Saúde Pública, 32(2), 1-10. https://doi.org/10.1590/0102-311X00045215
Basu, M. (2021). History of indigenous pharmaceutical companies in colonial Calcutta (1855-1947). Taylor & Francis.
Cassiolato, J. E. y Lastres, H. M. M. (2007). Inovação e sistemas de inovação: Relevância para a área de saúde. Revista Eletrônica de Comunicação Informática & Inovação em Saúde, 1(1), 153-162. https://doi.org/10.29397/reciis.v1i1.890
Chandran, N. y Brahmachari, S. K. (2018). Policy as a driver of economic growth: Historical evidence from the Indian pharmaceutical industry. Current Science, 114(6), 1181-1193. http://dx.doi.org/10.18520/cs/v114/i06/1181-1193
Chaturvedi, K., Chataway, J. y Wield, D. (2007). Policy, Markets and knowledge: Strategic synergies in Indian pharmaceutical firms. Technology Analysis & Strategic Management, 19(5), 565-588. https://doi.org/10.1080/09537320701521309
Chaudhuri, S. (2010). R&D for development of new drugs for neglected diseases in India. International Journal of Technology and Globalisation, 5(1/2), 61-75. http://dx.doi.org/10.1504/IJTG.2010.033666
Falcão, D. y Paranhos, J. (2022). As políticas de inovação para a indústria farmacêutica da Índia entre 2005 e 2019: lições e aprendizados de um país em desenvolvimento. Textos de Economia, 25(2), 1-23. https://doi.org/10.5007/2175-8085.2022.e91179
Gadelha, C. (2006). Desenvolvimento, complexo Industrial da saúde e política industrial. Revista de Saúde Pública, 40, 11-23. http://dx.doi.org/10.1590/S0034-89102006000400003
Gadelha, C. (2021). O Complexo Econômico-Industrial da Saúde 4.0: por uma visão integrada do desenvolvimento econômico, social e ambiental. Cadernos do Desenvolvimento, 16(28), 25-49.
Gadelha, C. (2022). Complexo Econômico-Industrial da Saúde: a base econômica e material do Sistema Único de Saúde. Cadernos de Saúde Pública, 38, 1-17. https://doi.org/10.1590/0102-311X00263321
Ghosh, S. (2014). Health sector reforms and changes in prevalence of untreated morbidity, choice of healthcare providers among the poor and rural population in India. International Journal of Health Policy and Management, 2(3), 125-130. http://dx.doi.org/10.15171/ijhpm.2014.32
Gonzalo, M. y Cassiolato, J. E. (2016). A evolução do Sistema Nacional de Inovação da Índia e seus desafios atuais: uma primeira leitura a partir do pensamento latino-americano. BRICS Policy Center, 4(4), 6-27.
Gonzalo, M. (2023). India from Latin America: peripherisation, statebuilding, and demand-led growth. Routledge.
Guennif, S. y Ramani, S. V. (2012). Explaining divergence in catching-up in pharma between India and Brazil using the NSI framework. Research Policy, 41, 430-441. https://doi.org/10.1016/j.respol.2011.09.005
IQVIA (2025). India Pharma Landscape: Regulatory Policy & IP Landscape.
Lavarello, P., Sztulwark, S., Mancini, M. y Juncal, S. (2021). Creative imitation in late industrializing countries: The case of biopharmaceutics in South Korea and India. Innovation and Development, 13(1), 133–152. https://doi.org/10.1080/2157930X.2021.1934259
Mushtaq, M. U. (2009). Public health in British India: A brief account of the history of medical services and disease prevention in colonial India. Indian Journal of Community Medicine, 34(1), 6-14. https://doi.org/10.4103/0970-0218.45369
Organización Mundial de la Salud. (2023). Global vaccine Market report 2022: A shared understanding for equitable access to vaccines. WHO.
Ray, A. S. (2008). Learning and innovation in the Indian pharmaceutical industry: The role of IPR and other policy interventions. RECIIS, 2(2), 71-77. https://doi.org/10.3395/reciis.v2i2.192en
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Manuel Gonzalo, Henrique Jorgielewicz Rogovschi
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The authors whose texts are published in this Journal surrender their ownership rights in favour of the editor in a non exclusive manner, i.e. the authors can enter into other independent and additional contracts to publish their text, e.g. including it in an institutional repository, thematic or otherwise, publish it in a book, or others, as long as it is overtly stated that the work was first published in this Journal.
The responsibility for each published paper as regards its content relies exclusively on its authors, holding the editors harmless for any legal liabilities.
The texts of the Journal shall be published under the Creative Commons 4.0 BY-NC-SA license. Therefore, the editors are free to:
1) Share, copy and redistribute the material using any means or format.
2) Adapt, remix, transform and create from the material, under the following conditions:
- a) Attribution — credit to this work must be given in an appropriate manner, providing a link to the license and indicating if changes have been made.
- b) Non-Commercial Use — no use may be made of the published material for commercial purposes.
- c) Share Equal — Authors remixing, transforming or creating from the material must distribute their contribution under the same license as the original.
